India, July 30 -- MiMed Group Inc. (MDXG), a biopharmaceutical company focused on regenerative medicines, has agreed to acquire Sanara MedTech Inc. (SMTI) in a transaction valued at $35 per share, or approximately $350 million.
Sanara specializes in regenerative surgical products, including its flagship CellerateRX Surgical Powder and BIASURGE Advanced Surgical Solution, and is preparing for a 2027 commercial launch of OsStic BioAdhesive Advanced Bone Fixation, a device designated as Breakthrough by the U.S. FDA. The merger will combine Sanara's surgical technologies with MiMedx's portfolio, expanding reach across collagen particulate, wound irrigation and bone fixation markets.
MIMEDX CEO Joseph H. Capper, stated that the combination wil...